American Society of Hirudotherapy

Whitmanin

Direct thrombin inhibitor homolog cataloged in the Chinese medicinal leech Whitmania pigra secretome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Whitmanin7.1 kDa
Molecular weight (kilodaltons) of Whitmanin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Whitmanin is documented mechanistically only; no human evidence. Whitmania pigra-derived TCM preparations are NOT FDA-cleared, and whitmanin has no FDA-approved derivative.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
7,100 Da
Source species
Whitmania pigra
Discovered
2018

Biological Targets

  • → thrombin (Factor IIa)

Key Citations

  1. Zhong S et al. (2007), Biomed Chromatogr · PMID 17370295
  2. Zhong S et al. (2008), Zhongguo Zhong Yao Za Zhi · PMID 19260310

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.